Osteonecrosis asociada al uso de bifosfonatos: A propósito de un caso clínico

Biphosphonates reduce the risk of skeletal events and are currently part of standards of therapy in myeloma. Recently, zoledronate and pamidronate have been linked to osteonecrosis of the jaw, specially after surgical dental procedures. We report a 84 year-old man with multiple myeloma who developed...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Anguita C,Timoleón, Agurto P,Jaime, Roa E,Iván, Laissle C,German
Lenguaje:Spanish / Castilian
Publicado: Sociedad Médica de Santiago 2006
Materias:
Acceso en línea:http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872006000900011
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:scielo:S0034-98872006000900011
record_format dspace
spelling oai:scielo:S0034-988720060009000112014-01-23Osteonecrosis asociada al uso de bifosfonatos: A propósito de un caso clínicoAnguita C,TimoleónAgurto P,JaimeRoa E,IvánLaissle C,German Diphosphonates Myeloma Zoledronic acid Biphosphonates reduce the risk of skeletal events and are currently part of standards of therapy in myeloma. Recently, zoledronate and pamidronate have been linked to osteonecrosis of the jaw, specially after surgical dental procedures. We report a 84 year-old man with multiple myeloma who developed spontaneous osteonecrosis of both jaws, after 36 months of therapy with zoledronate with a cumulative dose of 136 mg. We discuss the pathogenic mechanisms, and review the recommendations on prevention and management of this new complication for neoplastic patients under prolonged therapy with biphosphonatesinfo:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.134 n.9 20062006-09-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872006000900011es10.4067/S0034-98872006000900011
institution Scielo Chile
collection Scielo Chile
language Spanish / Castilian
topic Diphosphonates
Myeloma
Zoledronic acid
spellingShingle Diphosphonates
Myeloma
Zoledronic acid
Anguita C,Timoleón
Agurto P,Jaime
Roa E,Iván
Laissle C,German
Osteonecrosis asociada al uso de bifosfonatos: A propósito de un caso clínico
description Biphosphonates reduce the risk of skeletal events and are currently part of standards of therapy in myeloma. Recently, zoledronate and pamidronate have been linked to osteonecrosis of the jaw, specially after surgical dental procedures. We report a 84 year-old man with multiple myeloma who developed spontaneous osteonecrosis of both jaws, after 36 months of therapy with zoledronate with a cumulative dose of 136 mg. We discuss the pathogenic mechanisms, and review the recommendations on prevention and management of this new complication for neoplastic patients under prolonged therapy with biphosphonates
author Anguita C,Timoleón
Agurto P,Jaime
Roa E,Iván
Laissle C,German
author_facet Anguita C,Timoleón
Agurto P,Jaime
Roa E,Iván
Laissle C,German
author_sort Anguita C,Timoleón
title Osteonecrosis asociada al uso de bifosfonatos: A propósito de un caso clínico
title_short Osteonecrosis asociada al uso de bifosfonatos: A propósito de un caso clínico
title_full Osteonecrosis asociada al uso de bifosfonatos: A propósito de un caso clínico
title_fullStr Osteonecrosis asociada al uso de bifosfonatos: A propósito de un caso clínico
title_full_unstemmed Osteonecrosis asociada al uso de bifosfonatos: A propósito de un caso clínico
title_sort osteonecrosis asociada al uso de bifosfonatos: a propósito de un caso clínico
publisher Sociedad Médica de Santiago
publishDate 2006
url http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872006000900011
work_keys_str_mv AT anguitactimoleon osteonecrosisasociadaalusodebifosfonatosapropositodeuncasoclinico
AT agurtopjaime osteonecrosisasociadaalusodebifosfonatosapropositodeuncasoclinico
AT roaeivan osteonecrosisasociadaalusodebifosfonatosapropositodeuncasoclinico
AT laisslecgerman osteonecrosisasociadaalusodebifosfonatosapropositodeuncasoclinico
_version_ 1718436282259996672